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Program Evaluation of Population-
and System-Level Policies: Evidence
for Decision Making
Simon Walker , Aimee Fox , James Altunkaya, Tim Colbourn, Mike Drummond,
Susan Griffin, Nils Gutacker , Paul Revill, and Mark Sculpher
Background. Policy evaluations often focus on ex post estimation of causal effects on short-term surrogate outcomes.
The value of such information is limited for decision making, as the failure to reflect policy-relevant outcomes and
disregard for opportunity costs prohibits the assessment of value for money. Further, these evaluations do not
always consider all relevant evidence, other courses of action, or decision uncertainty. Methods. In this article, we
explore how policy evaluation could better meet the needs of decision making. We begin by defining the evidence
required to inform decision making. We then conduct a literature review of challenges in evaluating policies. Finally,
we highlight potential methods available to help address these challenges. Results. The evidence required to inform
decision making includes the impacts on the policy-relevant outcomes, the costs and associated opportunity costs,
and the consequences of uncertainty. Challenges in evaluating health policies are described using 8 categories: 1)
valuation space; 2) comparators; 3) time of evaluation; 4) mechanisms of action; 5) effects; 6) resources, constraints,
and opportunity costs; 7) fidelity, adaptation, and level of implementation; and 8) generalizability and external valid-
ity. Methods from a broad set of disciplines are available to improve policy evaluation, relating to causal inference,
decision-analytic modeling, theory of change, realist evaluation, and structured expert elicitation. Limitations. The
targeted review may not identify all possible challenges, and the methods covered are not exhaustive. Conclusions.
Evaluations should provide appropriate evidence to inform decision making. There are challenges in evaluating poli-
cies, but methods from multiple disciplines are available to address these challenges. Implications. Evaluators need to
carefully consider the decision being informed, the necessary evidence to inform it, and the appropriate methods.
Highlights
 Evaluating policies by estimating their causal effects on short-term surrogate outcomes is, in isolation, of
limited value for decision making.
 Evidence for informing decision making needs to link policies to relevant outcomes, costs, and associated
opportunity costs and reflect the magnitude and consequences of uncertainty in these estimations.
 Challenges in program evaluation range across defining the valuation space and comparators, understanding
mechanisms of action and effects, estimating opportunity costs, and external validity.
 Methods from multiple disciplines are available to address these challenges.
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Much of the applied health economic research of
population- and system-level health policies has focused
on the ex post estimation of the causal effects on short-
term surrogate outcomes using observational data.1,2
This literature has been supported by methodological
developments that facilitate causal inference.3 However,
the information produced by these studies is usually
insufficient for decision making. The failure to reflect the
impacts on policy-relevant outcomes, for which decision
makers can be held accountable (e.g., population health)
and the disregard for opportunity costs prohibits the
assessment of value for money.1,4 Further, the ex post
nature limits their value for decision making, since the
information they provide is necessarily available only
after the decision to introduce the policy has been
made, although it may be useful to inform subsequent
decisions (e.g., policy redesign). Studies that focus their
conclusions on what previous decisions achieved often
display limited consideration of future decisions study
results could inform (for example, the introduction of
similar policies in other countries). Decision makers need
information on a policy’s expected impact at different
points in its life cycle; for example, whether to introduce
it, maintain it, scale it up, or withdraw it. Further,
evidence-informed policy choices are not concerned only
with whether a policy should be implemented but also
with the timing of when it should be implemented in the
face of uncertainty or whether there is value in investing
in further research implementing a policy.
Economic evaluation methods, often using the frame-
work of decision analysis, have been developed to inform
a range of decisions, including whether the interventions
should be introduced, continued with, or disinvested
from by health care services and also to consider the
value of collecting additional evidence.5,6 However, these
methods have not been widely used to assess health poli-
cies. Kreif et al7 found that of 2419 health-related impact
evaluations identified from 2010 to 2016, only 42 (2%)
included an economic evaluation, and those were gener-
ally of poor quality. In contrast to evaluations of health
policies, the value for money of clinical interventions
(e.g., medicines, procedures, and diagnostics) is routinely
assessed in many countries,8 often through health tech-
nology assessment processes, although debates continue
about what are suitable methods.9
Until recently, there has been little attempt to inte-
grate program (or impact) evaluation with economic eva-
luation methods. However, recent research has started to
bring the two together and to integrate learning from
other fields such as epidemiology,10 to consider the value
for money of health policies.1,4 This article aims to
develop this further by exploring how evaluations could
better inform policy choices. We begin by defining the
evidence required in terms of the impacts on the policy-
relevant outcomes, the costs and associated opportunity
costs, and the magnitude and consequences of uncer-
tainty. Then we identify and categorize the key chal-
lenges encountered when evaluating policies. Finally, we
highlight approaches that have been applied and a series
of examples as signposts for readers who wish to explore
these methods further.
What Decision Is Being Informed and What
Evidence Is Required?
Economic evaluation informs policy choices by provid-
ing evidence on the benefits, costs, and opportunity costs
of alternative courses of action. An intervention would
be considered value for money if its benefits exceed its
opportunity costs (i.e., its benefits exceed the benefits
that could be generated by alternative use of the same
resources).11 Economic evaluation has been used within
health care to consider the value of clinical interventions
and by governments to consider the value of a wide
range of policies.8,12
To be informative, an economic evaluation needs to
report on outcome(s) of relevance to the decision mak-
er(s) involved, based on their objectives and responsibil-
ities.13 The outcomes not only refer to an intervention’s
planned benefits but also include any unintended conse-
quences that can result from policies.14 To facilitate con-
sistency in decisions and assessment of opportunity cost,
it is preferable that the outcomes reflect what is consid-
ered relevant to other potential uses of the same
resources (e.g., what outcomes would be considered if
the resources were instead used for the provision of par-
ticular treatments). An economic evaluation should then
proceed as the evidential assessment of the impact of the
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policies on those outcomes, which can be used to com-
pare the intervention’s outcomes with its opportunity
costs to determine if the former exceed the latter.
To evaluate value for money, it is necessary to com-
pare an intervention against relevant alternative courses
of action. This may constitute a defined set of mutually
exclusive options available to pursue specific objective(s),
which goes further than just comparing one policy speci-
fication with the status quo.11 For example, an evalua-
tion of a sugar-sweetened beverage tax might warrant
consideration of different ways of implementing a tax on
sugar. Similarly, a decision may not always be a dichot-
omy of whether to introduce a policy or not, and other
options may be considered; for example, whether to scale
up a policy or whether to invest in further research on a
policy’s impacts.
Evaluation is inevitably uncertain, reflecting incom-
plete evidence and knowledge. This uncertainty imposes
costs, as choosing the suboptimal policy has negative
implications for objectives. Here, we refer not to statistical
significance but to decision uncertainty, the probability
and consequences of incorrect decisions. Regardless of the
risk of error, decisions will have to be made about what
course of action to pursue at a given time. By assessing the
implications of the decision uncertainty, the decision
maker can assess the value of acquiring further evidence to
reduce it. On this basis, evidence-informed decision mak-
ing can expand on the range of decision options beyond
the ‘‘yes’’ or ‘‘no’’ to a given policy to include those such
as whether to delay an adoption decision until additional
evidence becomes available.5,15
Challenges in Evaluating Population and
Systems Interventions: A Targeted Literature
Review and Classification
We conducted a targeted literature review to identify key
challenges in undertaking economic evaluation of poli-
cies, many of which apply to any form of evaluation. We
identified articles by asking members of an Expert Advisory
Group (see supplementary material) for key papers, both
methodological and applied, on the evaluation of popula-
tion- and system-level policies. We reviewed the reference
list for these articles to identify further relevant publications.
In total, 40 methods articles and 2 reviews of applied papers
were identified (see supplementary material).
Each article was reviewed by one member of the
research team responsible for reviewing (S.W., A.C.,
J.A., and M.D.), and the details of any methods chal-
lenges raised were extracted. Following the review of all
articles, the entire research team (all coauthors) considered
the methods challenges raised and categorized them under
8 themes: 1) the valuation space; 2) comparators; 3) timing
of the evaluation; 4) mechanisms of action; 5) effects; 6)
resources, constraints, and opportunity costs; 7) fidelity,
adaptation, and level of implementation; and 8) generaliz-
ability and external validity. Supplementary Table S1 sets
out a brief description of each theme, the associated chal-
lenges, the problem(s) they entail, and key quotes. Below,
we summarize the challenges grouped under each theme.
Valuation Space
We define the valuation space as the set of policy-
relevant outcomes. When evaluating health care treat-
ments, the focus is often limited to their impact on the
health of patients, typically measured using generic
units of health such as the quality-adjusted life-year
(QALY). This may also be true when considering some
population- and system-level policies. However, broader
impacts may be relevant for some policies, including
those related to health (e.g., mortality) and health care
processes (e.g., access to care) but also non–health
related outcomes (e.g., labor market participation, finan-
cial protection).13,16–19 The unit of analysis for the out-
comes of interest may be at the individual level or higher
(e.g., firm, hospital).
Delineating and defining the relevant outcomes for
evaluation can be challenging. This is particularly the
case where there are different decision makers involved
with interests in varying outcomes.16–18 Expanding the
valuation space to multiple outcomes raises challenges
related to the measurement and valuation of the out-
comes (e.g., double counting) and to comparing them
with the outcomes generated by other policies.13 The
valuation space also needs to be broad enough to cap-
ture any unintended consequences.1 Economic evalua-
tion requires evidence of not only the direct effects of the
policies on all outcome(s) of interest but also of its
opportunity costs, which ideally would be expressed in
terms of these outcomes. Where there are improvements
in some outcomes and deterioration in others, some
method of aggregating across outcomes is required to
decide whether the policy is beneficial (whether done
informally or formally).13
Decision makers may also care about reducing unfair
inequalities in the outcomes.16,20 To consider these in an
evaluation, evidence on both the baseline distribution of
the outcomes and distribution of the policy effects (both
direct and opportunity costs) on the outcomes across
equity-relevant groups of interest is required.21 Further
information will be needed on the degree of inequality
aversion for the outcomes.22,23
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Comparators
We define the comparators as the set of alternative
courses of actions subject to evaluation. To establish
whether a policy is of value requires it to be compared
with other potential courses of action that could be used
to pursue the same objective(s). Evaluations of health
care interventions often focus on alternative options for
a single component within a treatment pathway, for
example, whether to provide drug A or B. However,
health care policies are typically more complex, poten-
tially consisting of multiple components that have an
impact across different points in multiple pathways.24,25
As such, there are, in principle, a large number of poten-
tial comparators, and establishing the expected impacts
of each on the relevant outcomes is analytically and com-
putationally challenging, if not impossible. One potential
comparator is the status quo, although this may differ
between settings and over time.25
Time of the Evaluation and Decisions
We refer to the time of the evaluation in respect to the
policy’s life cycle, which runs from its conception prior
to implementation, through initial roll out, to full imple-
mentation, and finally refinement and maturation. Dif-
ferent decisions are required at different time points in
its life cycle. Dependent on the timing of the evaluation,
there may be different evidential challenges to address.
For example, early on, the challenges may stem from
limited understanding of the possible outcomes.1 Later,
challenges may stem from lack of data on what the out-
comes would be without the policy (counterfactual). The
value of a policy may also change over time. For exam-
ple, if evaluating a policy with large upfront (potentially
sunk) costs, these would need to be considered when
evaluating whether to introduce it, but following its
introduction, these costs may be irrecoverable and do
not result in further opportunity costs when considering
whether to continue with the policy. The level of decision
uncertainty will also vary over time, and decision makers
may need to consider whether they require further infor-
mation to help inform the current decision and whether
a decision to implement the policy would prevent further
evidence generation or alternatively lead to further learn-
ing about its effects.6
Mechanisms of Action
The mechanisms of action are the causal chains and pro-
cesses on which a policy acts to produces its effects.
Health systems are complex with multiple interacting
constituent parts,26,27 many of which may be affected by
the introduction of a policy. The various potential
mechanisms of action are unlikely to be independent of
each other, and the overall impact of a policy will reflect
their joint effect, including any interactions or spillovers.
To evaluate the overall effect of a policy, it may be nec-
essary to understand how the changes resulting from its
introduction affect each constituent part and their inter-
actions, with the failure to do so potentially leading to
incorrect estimation of effects. For example, the intro-
duction of co-payments intended to reduce unnecessary
care was shown to reduce demand for health care for
those patients incurring the co-payments that, if consid-
ered in isolation, suggested it had the desired effect.28
However, further research demonstrated that physicians
responded by increasing care and costs to other patients
at the same practice, thus increasing unnecessary care.29
Estimating Effects
Establishing a causal relationship between a policy and
policy-relevant outcomes is necessary to determine its
value; however, it is challenging.1 For example, as noted
above, the effects of a policy are potentially dependent
on its impact and interaction with numerous constituent
parts,1 or it may not be easy to separate the impacts of
the policy from other changes occurring contempora-
neously.4,30 This is further complicated by the effects of
the policy evolving over time, for example, due to learn-
ing or bedding in processes.30,31 Health care policies may
also have important unintended consequences that will
need to be captured.1,4,25,29,30,32 The above all raise chal-
lenges around the appropriate methods to estimate a pol-
icy’s impacts, including estimation problems associated
with causal inference, understanding the processes by
which a policy affects outcomes, capturing any changes
over time, and having an appropriately broad perspec-
tive to capture both intended and unintended impacts.
Resources, Constraints, and Opportunity Costs
For clinical interventions, economic evaluation has used
cost-effectiveness thresholds to represent the maximum a
health care system might pay for additional health out-
comes. The threshold can represent an estimate at the
margin of how much health is lost elsewhere for a given
amount of expenditure being reallocated (i.e., it repre-
sents the opportunity cost).33 Using this approach, the
monetary cost of an intervention can be converted into
opportunity costs measured in the same metric as the
benefits (i.e., policy-relevant outcomes) to see whether
the benefits exceed the opportunity costs. Resource con-
straints are often depicted as a singular monetary
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constraint, for example, the health care budget. How-
ever, population- and system-level policies may affect
multiple budgets (e.g., primary and secondary care) and
other nonfinancial constraints (e.g., staff, capital equip-
ment, capacity), which can result in differential opportu-
nity costs per unit of expenditure depending on the
particular limits of each constraint.13,34–36
Because of their scale, some policies may have non-
marginal impacts, requiring very large amount of
resources (e.g., a new policy requiring a significant per-
centage of the health care budget) and/or inducing a
change in the overall production function (e.g., a new
technology that significantly affects the overall health
produced by the health care system) such that estimates
of the marginal productivity of health care expenditure no
longer reflect opportunity costs.37 Estimating the monetary
costs of a policy may itself be challenging, particularly if
they are subject to economics of scale (where the marginal
resource requirements of a policy decrease as its scale
increases) or economies of scope (where marginal resource
requirements are dependent on the other services being pro-
vided). Finally, the extent of the valuation space may
require understanding of opportunity costs on a wide set of
outcomes and that an estimate of opportunity cost related
to health and health care resources may not be sufficient.38
Fidelity, Adaptation, and Level of Implementation
A health care policy’s impacts reflect the way in which it
is applied and may be altered by factors such as the fide-
lity of its application, the intensity of effort to apply it,
the comprehensiveness with which it is applied, the level
of uptake, and the scale of implementation.30,39,40 These
may all differ over the life cycle of the policy. For exam-
ple, experience from the early stages of implementation
of a policy is frequently used to inform implementation
in the later stages, policies are not always clearly defined
and may evolve over time, and staff may adapt their
behavior to them.4 Evaluations should strive to take
these factors into consideration when assessing a policy.
Generalizability and External Validity
Generalizability refers to the utility of evidence outside
the time or setting in which it was generated. Program
evaluation methods that are highly focused on establish-
ing the internal validity of the evaluation are tied to the
setting in which the observations were made. However,
for decision making, external validity is vitally impor-
tant, particularly when decision makers are interested in
applying policies to alternative settings.41 The effects of
policies are likely to vary across settings and over time.
For example, one might expect financial incentives for
improving care to have different impacts in the United
Kingdom as compared with the United States, given dif-
ferences in the remuneration structure for clinicians.
Careful consideration needs to be given to whether the
evidence produced by an evaluation is applicable to the
decision being addressed.
What Are the Methods Available to Address
These Issues?
Many, if not all, of the challenges outlined are not unique
to population- or system-level interventions and arise
also in the evaluation of other interventions. Different
evaluations will be affected by these challenges to differ-
ing degrees, and there are no universal approaches or
methods to address all of them. In this section, we high-
light some potential approaches and methods available
to tackle these challenges and provide some examples in
which these approaches have been applied as signposts
for readers who wish to see further details.
What Outcomes to Capture and How Should They Be
Valued? Defining the Valuation Space
The choice of outcomes to capture represents a value
judgment about the key issues of consequence, and this
judgment should reflect the views of the relevant decision
makers, not the analyst.13 When considering which out-
comes to include, one potential approach is to determine
a set of outcomes and to estimate the impact on each of
them.13 When multiple outcomes are considered, an aggre-
gation function (a further value judgment) will need to be
imposed to determine if a policy is beneficial overall if
there are winners and losers.13 A cost-benefit analysis or
social return on investment approach would aggregate out-
comes by attaching monetary values, often derived
from individuals’ preferences, to each.11 Multicriteria
decision analysis can also be used to help reach consen-
sus on the impacts on multiple outcomes; however,
consideration needs to be given to consistency across
decisions and whether opportunity costs are appropriately
considered.42–44 An alternative approach is to define a single
(universal) outcome measure; examples include approaches
such at the QALY, capability approaches, or extended
QALYs.45–48 However, such an approach imposes a value
judgment that all issues of consequence and tradeoffs
between them are appropriately captured within the measure.
If a broad set of outcomes are relevant for decision
making, the approach of capturing the impacts on multi-
ple outcomes may be preferable. Further, by capturing
the outcomes individually, alternative value judgments
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around the appropriate methods of aggregation can be
considered. Recent examples, looking at policies for alco-
hol use disorder and air pollution policies, have shown
how the impacts on multiple outcomes can be estimated,
and different value judgments in their aggregation con-
sidered.13,49–51
What Decision Are We Trying to Inform?
Determining the decision options is likely to involve sig-
nificant scoping work and interactions with the decision
makers and other relevant stakeholders to determine the
range of options available.30
Deferring a decision on the implementation of a pol-
icy to conduct further research to inform a later decision
may be possible.5,52 The ability of a decision maker to
consider further research will depend on his or her
responsibilities and the nature of the policy being consid-
ered.5,6,53 Any evaluation will be undertaken in the face
of uncertainty, and reducing this uncertainty generates
benefits in terms of better decisions.54 Value-of-informa-
tion methods consider the value of further research to
reduce decision uncertainty. Research into the adoption
of new interventions expanded decision options away
from only ‘‘approve’’ or ‘‘reject’’ to include options such
as ‘‘only in research,’’ in which interventions are funded
only for those included in research studies or coverage
with evidence development, whereby an intervention is
funded for all while research is conducted.5,6,52 These
approaches could be used to inform policy decisions, for
example, before a policy’s introduction, a program of
further research including only a pilot or partial roll out
may be feasible to generate additional evidence.5,6
Vehicles for Evaluation
A key challenge in evaluating policies is establishing their
effects on relevant outcomes. This may require bringing
together evidence from a range of sources. There is a
continuum of approaches for evaluation, ranging from
empirical analysis of 1 or more data sets to decision ana-
lytic modeling approaches that synthesize evidence from
multiple sources.
Empirical approaches rely on having data available,
which includes measurements that can be used to estab-
lish the impacts of a policy over an appropriate time hor-
izon. The analysis by nature will be a retrospective
assessment of the value of the policy over that period in
that setting. As such, careful consideration needs to be
given to the relevance of the evidence for any subsequent
decisions within that or a different setting. In addition,
there may be several data sets, each of which has
potential relevance to a decision problem and should be
reflected in the evaluation.
Decision analytic modeling brings together evidence
from the range of available sources to estimate the
impacts of policies,11,55 often in unison with statistical
synthesis methods.56,57 Modeling approaches to valuing
policies can be broadly categorized in 2 ways: 1) linking
short-term impacts of the policies from empirical analy-
ses to longer-term outcomes modeled by the impact on
individual(s) and 2) modeling the impacts on the systems
and individuals jointly. The first of these involves no
explicit modeling of the impact of the policy on different
constituent parts of the system, instead taking an esti-
mate of the overall impact of these system effects on a
surrogate outcome (e.g., on mortality, length of stay)
from empirical or other studies and extrapolating the
change in the surrogate to the overall impacts on individ-
uals (e.g., QALYs). Recent evaluations using such an
approach include assessment of payment for perfor-
mance mechanisms with mortality impacts linked to life-
time health outcomes and costs.58–60 The second
approach models the system and its constituent parts.
Approaches under this range from mathematical pro-
gramming looking at aggregating the independent
impacts on the costs and outcomes resulting from differ-
ent constituent parts (e.g., treatments received), to com-
plex system modeling reflecting the interactions between
multiple constituent parts.34,61–63 The mathematical pro-
gramming approach to the allocation of health care
resources has been used to consider budgetary policies,
health system strengthening, and investment in resource
constraints.34,35,63–66 Dynamic simulation modeling, such
as system dynamic modeling and agent-based modeling,
have been used to simulate the impacts of health care pol-
icies on health care systems and their multiple constituent
parts.67,68 A recent review identified 39 studies that have
used such approaches to examine the impacts of health
care policies on targets such as overstretched resources,
length of stay, and undesirable patient outcomes.68
What Are the Expected Mechanisms of Action of the
Policy?
A key challenge in evaluation is understanding the way
a policy is expected to affect the relevant outcomes.
Theory-based approaches can be used to build this
understanding by defining the hypothesized causal
chains.69,70 Approaches such as mechanism mapping, in
which potential mechanism-context interactions are iden-
tified, or group model building, in which a diverse set of
practitioners collaborate to develop causal models, can
help to establish the expected effects and to provide
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suitable context-specific adaptations.71,72 Realist evalua-
tion can also play a role, focusing on the context-specific
nature of mechanisms of action to understand ‘‘what
works, for whom, under what circumstances.’’73,74 Artifi-
cial intelligence methods may also have a role in generat-
ing information on the mechanisms of action.75
Estimating Effects
Establishing a causal relationship between a policy and
the outcomes is necessary to determine its value. The esti-
mate of the impact could be on a singular overall measure
of effect, which could be a key driver of value or relate to
the impacts across different constituent parts of the system.
Before a policy is introduced, evidence on its impacts may
have to be taken from the literature or other settings, with
careful consideration given to its transferability to the con-
text being considered. Methods are available to help adapt
estimates in a transparent way (e.g., midrange theory76). If
no relevant empirical evidence exists, methods such as struc-
tured expert elicitation are available.77
If a program of research is planned to be conducted as
part of the roll out of a policy to inform a future deci-
sion, randomized controlled trials (RCTs) or similar
approaches may be feasible.53 Pandya et al.60 provided a
recent example of the use of an RCT to evaluate finan-
cial incentives to manage cholesterol levels. However,
RCTs have been subject to criticism for the evaluation of
policies, notably regarding limits on their external valid-
ity and whether the causal effects estimated in the experi-
mental setting generalize to ‘‘routine’’ contexts.78–80 If a
randomized comparison is not feasible, an organized
program of data collection using a study design that pro-
vides an opportunity for rigorous causal inference meth-
ods could be considered, although such methods are also
subject to issues of external validity.81 It may be desirable
to improve the external validity by considering the results
of different causal inference evaluations relevant to dif-
ferent contexts using an analytical modeling approach.
Choice of study design can be informed by an explicit
consideration of the value of the evidence generated
using value-of-information methods.82,83
For analyses following the introduction of a policy,
the use of quasi-experimental approaches to establishing
causality has been a key focus of the program evaluation
literature.3 These rely on the ability to identify a suitable
control against which to judge the policy. A recent exam-
ple used causal inference methods (synthetic controls) to
estimate a mortality impact and a decision analytic model
to extrapolate the results to estimate the cost-effectiveness
of the UK Quality and Outcomes framework.59
Generating Evidence on Costs and Opportunity Costs
To establish value for money of a health policy, it is
essential to estimate the opportunity costs. Challenges
arising from multiple budgets, nonfinancial constraints,
and nonmarginal impacts do not require significant
deviations from standard cost-effectiveness methods. For
multiple budgets or nonfinancial constraints, estimates
of the opportunity costs can be captured through mar-
ginal productivities for the outcome(s) of interest for
each budget or constraint.13,33,84,85 An evaluation of air
pollution strategies considered budgets in the National
Health Service (NHS), public health, and social care,
whereas nonfinancial constraints have been considered
in evaluations of eye care services in Zambia and viral
load testing in sub-Saharan Africa.34,35,54 When there are
nonmarginal impacts, evidence is required on the scale
of the impact and the change in the opportunity costs
per unit of expenditure.37 Lomas et al. considered the
implications of nonmarginal budget impacts on value for
money of new treatments for hepatitis C, which had been
estimated to cost the NHS more than £700m per annum
(0.7% of total NHS budget).37,86
The challenges raised here around financial costs
being used to estimate opportunity costs also raise issues
with the use of cost-benefit analysis methods (whereby
the benefits measured in monetary terms are directly
compared with the monetary costs),11 which typically
assume that opportunity cost is equal to monetary cost.
Recent research has considered the extension of cost-
benefit analysis approaches for evaluating public expen-
diture by considering the marginal value of public funds,
which is equal to the ratio of beneficiaries’ willingness to
pay and the net cost to the public sector.87
Reflecting System Complexity
Where there are significant interactions within the
system, estimating financial cost implications and the
effectiveness of policies in isolation may not be sufficient
for establishing value for money. Previous work has
shown how extensions to the mathematical programming
approach on which cost-effectiveness analysis is based can
be used to evaluate different types of system-strengthening
interventions.63,66 For example, Morton et al.66 conside-
red the optimal spend on system strengthening, which
increased the effectiveness of treatments in an HIV preven-
tion program. However, these approaches are informa-
tionally expensive, requiring estimates of the costs and
effects of all the independent interventions in the system
and the impact that the policies have on each of these.
Alternatively, others have highlighted the need to develop
Walker et al 7
whole-system models to evaluate policy outcomes and
opportunity costs. The Thanzi La Onse project is develop-
ing an individual-based comprehensive whole system and
an all-disease model of the Malawian health care system,
which will be capable of examining the impacts with and
without population- and system-level health policies.62
Considerations for the Analyst
In this section, we have signposted a range of approaches
of which we are aware to tackle challenges in evaluating
population- and system-level health policies. Many of the
approaches are not mutually exclusive and can be used in
combination, and the choice of methods requires consid-
ering their pros and cons in light of the specific evalua-
tion being undertaken. Further, the choice of methods
may be limited by the agency of the decision maker and
analyst and by the structural circumstances of the evalua-
tion. For example, where the decision maker lacks agency
in research, producing information on the value of fur-
ther research may be unwarranted. Evaluations are not
costless, and analysts will have to use their scientific judg-
ment to select approaches that are both appropriate and
feasible within the resources available. Regardless of the
approach taken, the analyst should engage with the deci-
sion makers involved to ensure the evaluation will pro-
vide appropriate evidence.
Conclusions
When evaluating health care policies, it is essential to
consider both their effects and their opportunity costs to
establish whether they represent value for money. How-
ever, program evaluation of population- and system-level
health policies has often focused on estimating causal
effects on short-term surrogate outcomes. These evalua-
tions are of limited value for decision making as they fail
to reflect the policy-relevant outcomes and disregards
opportunity costs. This article has aimed to show how
the evaluations of such policies could better inform deci-
sion making by defining the evidence required to inform
policy choices in terms of the impacts on the policy-
relevant outcomes of interest, the costs and associated
opportunity costs, and the magnitude and consequences
of uncertainty. The article also identified key challenges
described in evaluating population- and system-level
policies and examined methods that can address those
challenges. We would advocate that further method
development is necessary but that a multidisciplinary
approach bringing together health economics and adja-
cent fields such as epidemiology and mathematical
modeling will improve the evaluation of population- and
system-level policies.
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